The first new drug in decades specifically indicated for Hodgkin lymphoma and systemic anaplastic large cell lymphoma, ADCETRIS, has been approved for funding.
Exciting news for lymphoma patients!
The first new drug in decades specifically indicated for Hodgkin lymphoma and systemic anaplastic large cell lymphoma, ADCETRIS, has been approved for funding.
The pan-Canadian Pricing Alliance (PCPA) and Seattle Genetics have reached an agreement to fund ADCETRIS (brentuximab vedotin) for patients with relapsed or refractory Hodgkin lymphoma as well as patients with systemic anaplastic large cell lymphoma (sALCL). Effective February 3rd, 2014, INESSS approved funding for ADCETRIS for sALCL, but its funding for Hodgkin lymphoma is officially under review.
Participating provinces and territories in the PCPA will be moving forward with the implementation of their individual funding based on their usual processes. Please contact your individual provincial drug funding agency for more information. Reimbursement information can also be found at http://drugcoverage.ca/en-ca/.
-
Feb 19, 2014 : Cancer Care Ontario announced funding approval effective immediatly for Adcetris in sALCL and HL patients
In many instances, private insurance companies do fund ADCETRIS treatment, and patients who are covered under private insurance are advised to check with their carriers.
